Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 12/20 | 0.51 |
| ▸ | JAK2 | O60674 | 5/20 | 0.51 |
| ▸ | TYK2 | P29597 | 4/20 | 0.51 |
| ▸ | JAK3 | P52333 | 3/20 | 0.51 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13398084 | 0.84 | JAK1 (0.48) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL13398352 | 0.84 | JAK1 (0.47) | JAK1JAK2TYK2JAK3 | |
| Hydrochloric Acid SCHEMBL3314155 | 0.84 | JAK1 (0.48) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL13398364 | 0.83 | JAK1 (0.49) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL13398206 | 0.82 | JAK1 (0.59) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL13398410 | 0.77 | JAK3 (0.46) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL3312932 | 0.76 | JAK3 (0.59) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL3315303 | 0.76 | JAK3 (0.59) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL13398232 | 0.76 | JAK1 (0.42) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL2274036 | 0.75 | JAK1 (0.72) | JAK1JAK2TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105661-A1 | CONDENSED PYRIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100105661-A1 | CONDENSED PYRIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100105661-A1 | CONDENSED PYRIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-29 | — | — | US | disclosed |
| EP-2123651-A1 | CONDENSED PYRIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105661-A1 | CONDENSED PYRIDINE COMPOUND | JAK3, IRAK3, JAK1 | JAK1 3/4885JAK2 5/4885TYK2 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.